INMED PHARMACEUTICALS INC

INMNASDAQ

🏆 #3867 by market capEarnings Sep 23US Equity

$286.05▲ $11.99 (+4.19%)

Simulated price

1h—

24h▲ 4.2%

7d—

14d—

30d—

1y—

🏦Market Cap

$5M

Small Cap

📈Revenue Growth (YoY)

-32.8%

Declining

📊Gross Margin

35.9%

Healthy

💵FCF Margin

0.1%

Thin

⚖️P/S Ratio

1.4x

Cheap

Otter Score

Weak

No chart data available for INM.

Trading Snapshot

Day Range: $281.69 – $288.90
52-Week Range: $0.58 – $2.50
Volume: $1.66B
Avg Volume: $2.14B
Shares Outstanding: 3.3M
Next Earnings: Oct 25, 2026

Fundamentals Snapshot

Annual Revenue: $5M
Last Q Revenue: $1M
P/E Ratio: —
P/S Ratio: 1.4x
EPS (TTM): $-2.88
Dividend Yield: —

Why Investors Own INM

✓High-growth profile — revenue up +5.5% YoY with expanding US Equity exposure.
✓Healthy economics — 45% gross margin and 21% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$5M▲ +2.9% YoY

Gross Margin (TTM)

45.2%▲ +0.9% YoY

Operating Income (TTM)

$1M▲ +2.9% YoY

Free Cash Flow (TTM)

$1M▲ +2.9% YoY

About INMED PHARMACEUTICALS INC

InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.

🦦